Abstract
Pre-Clinical Development of a Highly Efficient TALEN ®-Based Correction of the β-Globin Gene in Patient-Derived Hematopoietic Stem and Progenitor Cells (HSPCs) to Treat Sickle Cell Disease
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have